Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia -A Pilot Study

References

• SoRelle R. Baycol withdrawn from market. Circulation 2001;104:E9015–E9016
   Web of Science ®Google Scholar
• Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001;323:359
   Web of Science ®Google Scholar
• Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety 2000 23:197–213
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 2000;21:353–64
   PubMed Web of Science ®Google Scholar
• Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep 2000;2:14–19
   PubMedGoogle Scholar
• Illingworth DR, Bacon S. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 1989;9(Suppl 1):I121–I134
   PubMedGoogle Scholar
• Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582–7
   PubMed Web of Science ®Google Scholar
• McPherson R, Angus C, Murray P, Genest J Jr for the WATCH Investigators. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women’s Atorvastatin Trial on Cholesterol (WATCH). Am Heart J 2001;141:949–56
   PubMed Web of Science ®Google Scholar
• Muls E, De Backer G, Brohet C, Heller F for the LIPI-GOAL investigators. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiol 2001;56:109–14
   PubMed Web of Science ®Google Scholar
• Bo M, Nicolello MT, Fiandra U, Mercadante G, Piliego T, Fabris F. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs. simvastatin. Nutr Metab Cardiovasc Dis 2001;11:17–24
   PubMed Web of Science ®Google Scholar
• Frost RJA, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87: 44–8
   Google Scholar
• McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001;88:270–74
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000;16(2):139–46
   PubMed Web of Science ®Google Scholar
• Illingworth DR, Crouse JR III, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O’Grady L, Mercuri M, Mitchel YB. Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17(1):43–50
   PubMed Web of Science ®Google Scholar
• Tompson GR. A Handbook of Hyperlipidaemia. Current Science: London, 1989
   Google Scholar
• Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000;40:637–44
   PubMedGoogle Scholar
• Kolovou G. The treatment of coronary heart disease: statins beyond cholesterol lowering. Curr Med Res Opin 2001;17(1):34–37
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47–51
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933–5
   PubMed Web of Science ®Google Scholar
• Cohen JD, Drury JH, Ostdiek J, Finn J, Veerendra Babu BR, Flaker G, Belew K, Donohue T, Labovitz A. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? Am Heart J 2000;139:734–8
   PubMed Web of Science ®Google Scholar
• Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–9
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442–9
   PubMed Web of Science ®Google Scholar
• Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000;152: 359–66
   Google Scholar
• Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999;34: 95–101
   Google Scholar
• Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 2001;157:75–84
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993–9
   PubMed Web of Science ®Google Scholar
• Elisaf M. The treatment of coronary heart disease: an overview of the risk factors for cardiovascular disease. Curr Med Res Opin 2001;17(1):18–26
   PubMed Web of Science ®Google Scholar
• Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2:197–205
   PubMedGoogle Scholar
• Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia – a pilot study involving serial sampling. Curr Med Res Opin 2001;16(4):269–75
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001;155:463–6
   Google Scholar
• Kakafika A, Tsimihodimos V, Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 2001;158:255
   Web of Science ®Google Scholar
• Cromwell WC, Ziajka PE. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol 2000;86:1123–7
   PubMed Web of Science ®Google Scholar
• Nozue T, Nohara A, Higashikata T, Mabuchi H, Kajinami K, Koizumi J. Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. Atherosclerosis 2000;153:525–6
   PubMed Web of Science ®Google Scholar
• Kostner KM. Aggressive therapy and combination therapy in severe hyperlipidemia. Wien Med Wochenschr 1999;149: 146–8
   PubMedGoogle Scholar